Literature DB >> 1672588

Intermittent vs maintenance medication in schizophrenia. Two-year results.

M I Herz1, W M Glazer, M A Mostert, M A Sheard, H V Szymanski, H Hafez, M Mirza, J Vana.   

Abstract

This is a 2-year, double-blind, placebo-controlled study of 101 patients, evaluating the relative efficacy of intermittent medication (given only when the patient shows early signs of relapse) compared with moderate doses of maintenance medication for stable schizophrenic outpatients. Patients were dropped from the study if they had three prodromal episodes in 1 year or if an episode lasted more than 9 weeks. Fourteen percent of patients given maintenance treatment were dropped from the study compared with 46% of intermittently treated patients. Relapse rates were 16% for patients given maintenance treatment and 30% for intermittently treated patients, a nonsignificant difference. Intermittently treated patients were receiving significantly less medication, but there were no differences found in drug side effects. There appears to be no advantage in using the intermittent approach, but we found that the use of an early intervention strategy reduced the relapse and rehospitalization rates for these patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1672588     DOI: 10.1001/archpsyc.1991.01810280049007

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  25 in total

1.  Symptom control and patient adherence to treatment: key goals in the treatment of psychosis.

Authors:  Marios Adamou
Journal:  Psychiatry (Edgmont)       Date:  2004-07

Review 2.  [Pharmacotherapy for schizophrenia].

Authors:  W W Fleischhacker; W Hummer
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

3.  Antipsychotic treatment patterns and hospitalizations among adults with schizophrenia.

Authors:  Susan dosReis; Elizabeth Johnson; Donald Steinwachs; Charles Rohde; Elizabeth A Skinner; Maureen Fahey; Anthony F Lehman
Journal:  Schizophr Res       Date:  2008-02-05       Impact factor: 4.939

4.  Dopamine D2 receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects.

Authors:  Ryosuke Arakawa; Hiroshi Ito; Akihiro Takano; Masaki Okumura; Hidehiko Takahashi; Harumasa Takano; Yoshiro Okubo; Tetsuya Suhara
Journal:  Psychopharmacology (Berl)       Date:  2010-03-27       Impact factor: 4.530

5.  Psychosocial rehabilitation for the mentally disabled: what have we learned?

Authors:  M Gittelman
Journal:  Psychiatr Q       Date:  1997

Review 6.  Review: treatment of schizophrenia. State of the art.

Authors:  H J Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

Review 7.  Antipsychotic medication for early episode schizophrenia.

Authors:  John Bola; Dennis Kao; Haluk Soydan
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 8.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 9.  Antipsychotic dosing: found in translation.

Authors:  Gary Remington; Gagan Fervaha; George Foussias; Ofer Agid; Peter Turrone
Journal:  J Psychiatry Neurosci       Date:  2014-07       Impact factor: 6.186

10.  Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States.

Authors:  Nicolas M Furiak; Haya Ascher-Svanum; Robert W Klein; Lee J Smolen; Anthony H Lawson; Robert R Conley; Steven D Culler
Journal:  Cost Eff Resour Alloc       Date:  2009-04-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.